[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350784-105":59,"doc-detail-350784-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nintedanib-inhibits-the-vegfrerk-signaling-pathway-in-human-kras-mutated-cancer-cells","Nintedanib inhibits the VEGFR–ERK signaling pathway in human KRAS-mutated cancer cells","","KRAS mutations drive multiple cancers, yet direct drug discovery targeting them has had limited success, requiring more effective therapies. Screening of 1,374 compounds identified nintedanib, a VEGFR inhibitor with potent, selective antiproliferative activity in KRAS-mutant cells. Nintedanib suppressed tumor growth in KRAS-mutant xenograft mice, reduced phosphorylated VEGFR2 and downstream pAKT/pERK signaling, and in VEGFR2-knockout cells lowered SOS1-dependent KRAS-GTP activity, promoting apoptosis. KRASG12D increased VEGFR2, forming a positive KRAS–VEGFR2 feedback loop within ERK signaling, and pancreatic tissues showed high VEGFR2 expression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nintedanib-inhibits-the-vegfrerk-signaling-pathway-in-human-kras-mutated-cancer-cells/350784/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nintedanib-inhibits-the-vegfrerk-signaling-pathway-in-human-kras-mutated-cancer-cells/350784.png","ImageObject",300,407,{"name":92,"@type":93},"CatatanPagi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What compound was identified as active against KRAS-mutant cancer cells in the screening study?","Question",{"text":112,"@type":113},"The screening library identified nintedanib as a VEGFR inhibitor with potent and selective antiproliferative effects against KRAS-mutant cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does nintedanib affect VEGFR2 signaling in KRAS-mutant cells?",{"text":117,"@type":113},"Nintedanib suppresses phosphorylated VEGFR2 and inhibits downstream signaling molecules pAKT and pERK in KRAS-mutant cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links SOS1 and KRAS-GTP activity when VEGFR2 is inhibited?",{"text":121,"@type":113},"In VEGFR2-knockout cells, inhibition of SOS1 reduces KRAS-GTP activity, which decreases ERK and AKT phosphorylation and induces apoptosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350784,1790142140,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962090894170,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nNintedanib inhibits the VEGFR–ERK signaling pathway inhuman KRAS-mutated cancer cells  \nSivasundaram Karnan 1,12 ✉, Akinobu Ota 1,2,12 ✉, Muhammad Nazmul Hasan 1,3,4,12, Toshinori Hyodo1, Nushrat Jahan1,3,4, Hideki Murakami5, Md Towhid Ahmed Shihan1,3, Ichiro Hanamura 6, Lam Quang Vu6, Miho Riku5, Hideaki Ito5, Yoshifumi Kaneko5, Yinzhi Lin7, Md Wahiduzzaman 8, Md. Lutfur Rahman9, Shingo Inaguma 10, Takuya Matsui11, Hiroyuki Konishi 1,  \nShinobu Tsuzuki 1 and Yoshitaka Hosokawa1  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | KRAS mutations are signiﬁcant drivers in various cancers, and existing drug discovery attempts targeting these mutations have largely been unsuccessful, emphasizing the need for more effective therapies. In this study, the screening library, which contains 1,374 chemical compounds, identiﬁed nintedanib, a VEGFR inhibitor, as exerting a potent and selective antiproliferative effect against KRAS-mutant cells, surpassing other VEGFR inhibitors. Nintedanib effectively suppressed tumor growth in xenografted mice with KRAS mutations and signiﬁcantly inhibited phosphorylated VEGFR2 levels and its downstream signaling molecules pAKT and pERK in KRAS-mutant cells, suggesting that VEGFR2 inhibition affects the oncogenic AKT/ERK pathway. Moreover, in VEGFR2-knockout cells, inhibition of SOS1 protein reduced KRAS-GTP activity, which decreased the phosphorylation of ERK, AKT, and DRP1, thereby inducing apoptosis. Remarkably, KRASG12D overexpression augmented VEGFR2 expression, establishing a positive feedback loop between KRAS mutations and VEGFR2 signaling within the ERK pathway. Immunohistochemical analyses of pancreatic cancer tissues revealed high VEGFR2 expression in 83%(67/80) of samples, signiﬁcantly exceeding the levels observed in normal pancreatic tissues. These results underscore VEGFR2 as a promising molecular target and propose a novel therapeutic avenue for |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| KRAS-mutant cancers. |  |  |\n|  | Cell Death and Disease (2026)17:780; [https://doi.org/10.1038/s41419-026-09015-2](https://doi.org/10.1038/s41419-026-09015-2) |  |\n|  |  |  |\n\nINTRODUCTION  \nKRAS mutations play a vital role in the development and progression of various cancers, particularly pancreatic, colorectal, and lung cancers [1–3] . The high mutation rate of KRAS in pancreatic cancer, estimated at 70%–90%, correlates with a poor 5-year survival rate of \u003C5%, emphasizing the urgent need for more effective therapeutic strategies [2, 4, 5] . Although the EGFR kinase inhibitor erlotinib has received approval as a treatment choice, its impact on survival has been limited [5–9] . In colorectal cancer, anti-EGFR monoclonal antibodies have been successfully deployed; however, the presence of RAS mutations severely compromises their efﬁcacy, thereby rendering them ineffective [6, 7, 10, 11] . Similarly, in the context of lung cancer, although erlotinib is commercially available for patients with EGFR mutations, it has been demonstrated to be ineffective in those with KRAS mutations [12] .  \nNevertheless, in recent years, advancements in drug discovery and deeper understanding of KRAS biology have resulted in some breakthroughs. For instance, the development of small molecule  \ninhibitors that speciﬁcally target KRASG12C mutations has shown promise in preclinical studies and clinical trials. Drugs such as sotorasib (AMG 510) and adagrasib (MRTX849) have received attention for their ability to selectively inhibit the G12C variant of KRAS, resulting in signiﬁcant clinical responses in patients with tumors harboring this speciﬁc mutation [10, 11, 13–17] . Nevertheless, a broader challenge remains because several variants lack a deﬁned binding pocket for effective inhibitor binding. Therefore, research continues to reﬁne our understanding of RAS biology and develop inno","cbCaiaDBHBQV7rQU","https://ap.wps.com/l/cbCaiaDBHBQV7rQU","pdf",3788340,16,"English","# Introduction\n## KRAS mutations and cancer impact\n## Limits of current KRAS-targeting strategies\n## Emergence of KRASG12C inhibitors and remaining challenges","[{\"question\":\"What compound was identified as active against KRAS-mutant cancer cells in the screening study?\",\"answer\":\"The screening library identified nintedanib as a VEGFR inhibitor with potent and selective antiproliferative effects against KRAS-mutant cells.\"},{\"question\":\"How does nintedanib affect VEGFR2 signaling in KRAS-mutant cells?\",\"answer\":\"Nintedanib suppresses phosphorylated VEGFR2 and inhibits downstream signaling molecules pAKT and pERK in KRAS-mutant cells.\"},{\"question\":\"What mechanism links SOS1 and KRAS-GTP activity when VEGFR2 is inhibited?\",\"answer\":\"In VEGFR2-knockout cells, inhibition of SOS1 reduces KRAS-GTP activity, which decreases ERK and AKT phosphorylation and induces apoptosis.\"}]","Nintedanib inhibits the VEGFR–ERK signaling pathway in human KRAS-mutated cancer cells | PDF",1790091076,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de4818ab310674b59ec84773e761a4cb.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef136572ea1a610e9099effb2b990cc9.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec2cbf49bd4e944f61123073c0448711.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f486365689446d336930cd88a1d3ca09.webp",980,1301]